The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of ...

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Biotech has lagged even more. The S&P Biotechnology Select Industry Index has returned about 3 per cent annually over 10 ...